Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   19915 News 


«12...157158159160161162163164165166167...203204»
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Analysis of Deficiency of Adenosine Deaminase 2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_3470;    
    P=N/A
    Overall, each monocyte subtype of DADA2 patients showed upregulation of immune response gene sets compared to controls. DADA2 patients have increased numbers of nonclassical monocytes which may contribute the immune dysregulation and increased inflammation observed in the disease.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Genetic prediction profile for adalimumab response in Slovenian Crohn's disease patients. (Pubmed Central) -  Nov 6, 2019   
    Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019  Our study supports the reported genetic anti-TNF response profile and extends it for adalimumab prediction.
  • ||||||||||  Review, Journal:  A Systematic Review of Treatment Strategies for Erythrodermic Psoriasis. (Pubmed Central) -  Nov 5, 2019   
    A fair number of poor-quality studies support the use of various biologic and systemic therapies in the treatment of EP. Treatment of EP should be based on the severity of the clinical scenario as well as patient comorbidities.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Systemic biological treatment in ophthalmology (Pubmed Central) -  Nov 3, 2019   
    In all cases, emerging new, biological therapy (adalimumab) was necessary to achieve permanent inactive period of uveitis and the autoimmune disease...Orv Hetil. 2019; 160(44): 1744-1750.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Biomarker, Clinical, Observational data, Journal:  Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. (Pubmed Central) -  Nov 2, 2019   
    We confirm serum drug level to be the most important factor determining treatment response, highlighting the need to take drug levels into account when searching for biomarkers of response. This real-world study with pragmatic drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is relevant to other inflammatory diseases.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Trial completion, Enrollment change, Trial completion date:  TURA: Targeted Ultrasound in Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 1, 2019   
    P4,  N=183, Completed, 
    This real-world study with pragmatic drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is relevant to other inflammatory diseases. Active, not recruiting --> Completed | N=400 --> 183 | Trial completion date: Dec 2018 --> Jul 2019
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
    Clinical, Journal:  Demographic and Clinical Patterns of Rheumatoid Arthritis in an Emirati Cohort from United Arab Emirates. (Pubmed Central) -  Oct 31, 2019   
    In this study, we describe disease features that are unique to United Arab Emirates (UAE) patients and demonstrate that RA has a significant disease burden. Our findings highlight the need for a RA national registry to improve the quality of care of these patients in UAE.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Recall Urticaria in Adalimumab Hypersensitivity. (Pubmed Central) -  Oct 30, 2019   
    Our findings highlight the need for a RA national registry to improve the quality of care of these patients in UAE. No abstract available
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Adalimumab in Psoriasis: How Much Is Enough? (Pubmed Central) -  Oct 28, 2019   
    Wilkinson et al. explore these questions in a real-world psoriasis cohort on adalimumab monotherapy, defining a therapeutic range and finding value in early measurement for predicting clinical response.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Journal:  TNF inhibitors for psoriasis. (Pubmed Central) -  Oct 25, 2019   
    An understanding of these idiosyncrasies can help guide therapeutic decisions for patients with psoriasis that also have inflammatory bowel disease, hepatitis C, hepatitis B, latent tuberculosis, obesity, cardiovascular disease, and heart failure. It can also help when selecting the right treatment for pregnant patients, children and adolescents, or those with insurance constraints or compliance issues.
  • ||||||||||  Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Targeted therapies for pediatric psoriasis. (Pubmed Central) -  Oct 25, 2019   
    In Europe, adalimumab is also approved for pediatric psoriasis for 4 years of age and older. While biologics have the advantage of less frequent administration, greater and more rapid efficacy than methotrexate, fewer side effects, and a less rigorous need for monitoring, their cost is much higher than that of methotrexate and other systemic medications, concerns about the development of neutralizing antibodies necessitate continuous treatment, and their long-term safety profile remains to be determined.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. (Pubmed Central) -  Oct 25, 2019   
    Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS...In this article, we summarize the existing data on biologics and other small-molecule systemic agents, as well as share our personal experiences with the pharmacological management of HS in the clinical setting. Continued challenges that limit our ability to study and treat this disease effectively include a lack of a universally employed scoring system for disease severity, high variability in clinical presentation, high cost of off-label therapy, and the scarcity of long-term studies on treatment response and medication safety.
  • ||||||||||  Orencia (abatacept) / BMS, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
    A SUCCESSFUL TREATMENT WITH ABATACEPT IN STEROID RESISTANT FOCAL SEGMENTAL GLOMERULOSCLEROSIS () -  Oct 25, 2019 - Abstract #IPNA2019IPNA_20;    
    Herein we present our experience with abatacept, a cytotoxic Tlymphocyte-associated antigen 4-immunoglobulin fusion protein (CTLA-4-Ig), in a patient diagnosed with primary FSGS and resistant to steroid, cyclosporine A (CsA), Mycofenolat mophetinile (MMF) and rituximab...After administration of abatacept, proteinuria level decreased below 1 gram/day and serum albumin levels increased to 3 mg/dL. This case indicates that abatacept can be at least partially effective in FSGS with resistance to other immunsupressive therapies such as CsA, cyclophosphamide, MMF and rituximab.
  • ||||||||||  Clinical, Journal:  The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis. (Pubmed Central) -  Oct 24, 2019   
    The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis. Our data suggest that female sex was associated with a lower rate of response to treatment and of disease remission in patients with axSpA treated with antitumor necrosis factor-α drugs.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
    Biomarker, Journal:  Histone modifications associated with biological drug response in moderate-to-severe psoriasis. (Pubmed Central) -  Oct 24, 2019   
    In patients without PsA significant changes in methylated H3K4 were found between responders and non-responders to biological drugs at 3 and 6 months. Although further studies should confirm these results, these findings suggest that H3K27 and H3K4 methylation may contribute to patients' response to biological drugs in psoriasis.